PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 33.3% in February

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 9,200 shares, an increase of 33.3% from the February 13th total of 6,900 shares. Based on an average daily trading volume, of 29,000 shares, the short-interest ratio is currently 0.3 days. Currently, 0.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Several brokerages have issued reports on PYPD. HC Wainwright dropped their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, December 26th. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw began coverage on shares of PolyPid in a report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price objective on the stock.

PolyPid Trading Up 1.5 %

NASDAQ:PYPD traded up $0.05 during trading hours on Monday, reaching $3.03. 18,830 shares of the stock were exchanged, compared to its average volume of 13,279. PolyPid has a twelve month low of $2.37 and a twelve month high of $5.50. The company has a quick ratio of 1.00, a current ratio of 1.31 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average of $3.02 and a two-hundred day moving average of $3.23. The company has a market capitalization of $30.83 million, a price-to-earnings ratio of -0.62 and a beta of 1.27.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.23). On average, equities analysts predict that PolyPid will post -1.79 EPS for the current year.

Institutional Investors Weigh In On PolyPid

Several institutional investors have recently modified their holdings of PYPD. Rosalind Advisors Inc. increased its holdings in shares of PolyPid by 50.6% in the 4th quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock valued at $3,108,000 after acquiring an additional 343,353 shares during the period. AIGH Capital Management LLC boosted its stake in PolyPid by 21.8% during the 4th quarter. AIGH Capital Management LLC now owns 827,867 shares of the company’s stock worth $2,509,000 after purchasing an additional 148,199 shares during the period. Stonepine Capital Management LLC purchased a new position in PolyPid during the 3rd quarter worth $476,000. Finally, J. Goldman & Co LP purchased a new stake in PolyPid during the 4th quarter valued at approximately $391,000. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.